219 related articles for article (PubMed ID: 25437144)
21. Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.
George DM; Breinlinger EC; Friedman M; Zhang Y; Wang J; Argiriadi M; Bansal-Pakala P; Barth M; Duignan DB; Honore P; Lang Q; Mittelstadt S; Potin D; Rundell L; Edmunds JJ
J Med Chem; 2015 Jan; 58(1):222-36. PubMed ID: 25000588
[TBL] [Abstract][Full Text] [Related]
22. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.
Constantine KL; Mueller L; Metzler WJ; McDonnell PA; Todderud G; Goldfarb V; Fan Y; Newitt JA; Kiefer SE; Gao M; Tortolani D; Vaccaro W; Tokarski J
J Med Chem; 2008 Oct; 51(19):6225-9. PubMed ID: 18771253
[TBL] [Abstract][Full Text] [Related]
23. Development of novel molecular probes of the Rio1 atypical protein kinase.
Mielecki M; Krawiec K; Kiburu I; Grzelak K; Zagórski W; Kierdaszuk B; Kowa K; Fokt I; Szymanski S; Swierk P; Szeja W; Priebe W; Lesyng B; LaRonde-LeBlanc N
Biochim Biophys Acta; 2013 Jul; 1834(7):1292-301. PubMed ID: 23523885
[TBL] [Abstract][Full Text] [Related]
24. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
25. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
26. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.
Heron NM; Anderson M; Blowers DP; Breed J; Eden JM; Green S; Hill GB; Johnson T; Jung FH; McMiken HH; Mortlock AA; Pannifer AD; Pauptit RA; Pink J; Roberts NJ; Rowsell S
Bioorg Med Chem Lett; 2006 Mar; 16(5):1320-3. PubMed ID: 16337122
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).
Roth GJ; Heckel A; Brandl T; Grauert M; Hoerer S; Kley JT; Schnapp G; Baum P; Mennerich D; Schnapp A; Park JE
J Med Chem; 2010 Oct; 53(20):7287-95. PubMed ID: 20919678
[TBL] [Abstract][Full Text] [Related]
28. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
[TBL] [Abstract][Full Text] [Related]
29. Advancing the kinase field: new targets and second generation inhibitors.
Laufer S; Bajorath J
J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
[No Abstract] [Full Text] [Related]
30. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
Badrinarayan P; Sastry GN
J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
[TBL] [Abstract][Full Text] [Related]
31. Computational investigation of TGF-β receptor inhibitors for treatment of idiopathic pulmonary fibrosis: Field-based QSAR model and molecular dynamics simulation.
Li W; Liu X; Muhammad S; Shi J; Meng Y; Wang J
Comput Biol Chem; 2018 Oct; 76():139-150. PubMed ID: 30015175
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
Chaudhary D; Robinson S; Romero DL
J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
[TBL] [Abstract][Full Text] [Related]
34. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes.
Köster H; Craan T; Brass S; Herhaus C; Zentgraf M; Neumann L; Heine A; Klebe G
J Med Chem; 2011 Nov; 54(22):7784-96. PubMed ID: 21972967
[TBL] [Abstract][Full Text] [Related]
35. Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water thermodynamics.
Horbert R; Pinchuk B; Johannes E; Schlosser J; Schmidt D; Cappel D; Totzke F; Schächtele C; Peifer C
J Med Chem; 2015 Jan; 58(1):170-82. PubMed ID: 25007344
[TBL] [Abstract][Full Text] [Related]
36. Selectivity-determining residues in Plk1.
Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
[TBL] [Abstract][Full Text] [Related]
37. Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors.
Kolb P; Kipouros CB; Huang D; Caflisch A
Proteins; 2008 Oct; 73(1):11-8. PubMed ID: 18384152
[TBL] [Abstract][Full Text] [Related]
38. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
[TBL] [Abstract][Full Text] [Related]
39. Fragment-based approaches to the discovery of kinase inhibitors.
Mortenson PN; Berdini V; O'Reilly M
Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
Andrs M; Korabecny J; Jun D; Hodny Z; Bartek J; Kuca K
J Med Chem; 2015 Jan; 58(1):41-71. PubMed ID: 25387153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
